The SEVUSMART study aims to assess the safety of escalating doses of sevuparin in up to 20 children aged 3 months to 12 years diagnosed with severe malaria at study sites in Kenya and Zambia. By determining the optimal dose of sevuparin in combination with the current standard of care, the study seeks to pave the way for further clinical development.

Sevuparin, Modus’ proprietary drug candidate, has previously demonstrated promising effects against the malaria parasite in both uncomplicated malaria patients and in ex vivo studies (Leitgeb et al. 2017, Saiwaew et al. 2017). By targeting key mechanisms of severe malaria pathophysiology, sevuparin has the potential to reduce disease severity and improve patient outcomes.

“The successful completion of patient enrollment marks an important milestone for the SEVUSMART study and is a testament to the dedication of Professor Kathryn Maitland and her research team at Imperial College London and the KEMRI-Wellcome Trust Programme in Kilifi, Kenya, as well as the hardworking study teams in Kenya and Zambia. We are proud to be part of this important collaborative effort and look forward to the upcoming study results,” says John Öhd, CEO, Modus Therapeutics.

Severe malaria remains a major global health challenge, particularly for young children in malaria-endemic regions. The results from SEVUSMART will provide critical insights to the future clinical research evaluating sevuparin as an adjunctive treatment for this devastating disease.